Skip to main content

Advertisement

SpringerLink
Log in

A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate clinical remission and MDA in PsA patients who started TNF-inhibitors (TNFi) treatment with a 2-year follow-up. Concomitant therapies as well as comorbidities were assessed. Level of concordance of clinimetric indices and the potential predictive factors of remission/MDA were also evaluated. Clinical and laboratory evaluations were prospectively performed in PsA patients at baseline (T0) and after 22 (T22), 54 (T54), and 102 (T102) weeks of treatment. Disease activity and disability were assessed using DAS28, CPDAI, DAPSA, MDA, and HAQ-SpA. The Pearson correlation coefficient, univariate, and multivariate binary logistic regression were performed. A total of 221 PsA patients were included. Cardiovascular diseases and metabolic syndrome (MetS) resulted as the most frequent comorbidities. Clinical remission was achieved by over a half of the patients during the follow-up. Use of concomitant therapies, such as csDMARDs and steroids, was significantly reduced during the follow-up. Agreement among indices of treatment targets by k-statistics was excellent for CPDAI and DAPSA and good for MDA and DAS28 or DAPSA. Female sex and MetS resulted as negative prognostic factors of clinical remission and MDA at all the time points. TNFi are highly effective in achieving treatment targets in PsA patients. DAS28, CPDAI, DAPSA, and MDA show a good agreement. Female sex and MetS are associated with a lower probability to achieve remission in PsA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Christophers E (2001) Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 26:314–320

    Article  CAS  PubMed  Google Scholar 

  2. Conigliaro P, Chimenti MS, Triggianese P, Sunzini F, Novelli L, Perricone C, Perricone R (2016) Autoantibodies in inflammatory arthritis. Autoimmun Rev 15:673–683

    Article  CAS  PubMed  Google Scholar 

  3. Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42:1460–1468

    Article  CAS  Google Scholar 

  4. Chimenti MS, Triggianese P, Conigliaro P, Santoro M, Lucchetti R, Perricone R (2014) Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity. Drug Dev Res:S57–S59

  5. Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R (2013) Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 12:599–606

    Article  CAS  PubMed  Google Scholar 

  6. Scrivo R, Conigliaro P, Riccieri V, Di Franco M, Alessandri C, Spadaro A, Perricone R, Valesini G (2015) Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. Clin Exp Immunol 179:300–308

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Coates LC, Kavanaugh A, Mease PJ et al (2016 May) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060–1071

    PubMed  Google Scholar 

  8. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P et al (2014) Targeting spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis:736–716

  9. Coates l, Helliwell P. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965–969

  10. Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24:83–87

    Google Scholar 

  11. Lubrano E, Perrotta FM, Kavanaugh A (2015) Clin Exp Rheumatol 33:S51–S54

    PubMed  Google Scholar 

  12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) CASPAR study group: classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673

    Article  PubMed  Google Scholar 

  13. Castrejón I, Ortiz AM, Toledano E, Castañeda S, García-Vadillo A, Patiño E, González-Alvaro I (2010) Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritis. J Rheumatol 37:1439–1443

    Article  PubMed  Google Scholar 

  14. Mumtaz A, Gallagher P, Kirby B et al (2011) Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70:272–277

    Article  PubMed  Google Scholar 

  15. Helliwell PS, Fitzgerald O, Fransen J et al (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72:986–989

    Article  PubMed  Google Scholar 

  16. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64:Suppl 2:ii49–2:ii54

  17. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

    Article  CAS  PubMed  Google Scholar 

  18. Temizkan S, Balaforlou B, Ozderya A, Avci M, Aydin K, Karaman S, Sargin M (2016) Effects of thyrotrophin, thyroid hormones, and thyroid antibodies on metabolic parameters in a euthyroid population with obesity. Clin Endocrinol. doi:10.1111/cen.13095

  19. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645

    Article  CAS  PubMed  Google Scholar 

  20. Moll JM, Wright V (1973) Psoriatic arthritis. Seminars arthritis Rheum 3:55–78

    Article  CAS  Google Scholar 

  21. Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M et al (2012) Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 225:312–319

    Article  CAS  PubMed  Google Scholar 

  22. Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, Choi HK (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71:1273–1277

    Article  PubMed  PubMed Central  Google Scholar 

  23. Maillefert JF, Combe B, Goupille P, Cantagrel A, Dougados M (2004) The 5-yr HAQ-disability is related to the first year’s changes in the narrowing, rather than erosion score in patients with recent-onset rheumatoid arthritis. Rheumatology (Oxford) 43:79–84

    Google Scholar 

  24. Hotamisligil GS (2006) Nature 444:860–867

    Article  CAS  PubMed  Google Scholar 

  25. Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195–202

    Article  Google Scholar 

  26. Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 72:1956–1961

    Article  CAS  PubMed  Google Scholar 

  27. Chimenti MS, Triggianese P, Conigliaro P, Candi E, Melino G, Perricone R (2015) The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis 6:e1887

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Haroon M, Gallagher P, Heffernan E, FitzGerald O (2014) High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 41:1357–1365

    Article  PubMed  Google Scholar 

  29. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68:1387–1394

    Article  CAS  PubMed  Google Scholar 

  30. Chimenti MS, Graceffa D, Perricone R (2011) Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 10:636–640

    Article  CAS  PubMed  Google Scholar 

  31. Chimenti MS, Teoli M, Saraceno R, Dattola A, Ventura A, Chiricozzi A et al (2013) Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology 227:305–310

    Article  CAS  PubMed  Google Scholar 

  32. Bergamini A, Chimenti MS, Baffari E, Guarino MD, Gigliucci G, Perricone C, Perricone R (2014) Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis. PLoS One 9:e92018

    Article  PubMed  PubMed Central  Google Scholar 

  33. Conigliaro P, Triggianese P, Perricone C, Chimenti MS, Di Muzio G, Ballanti E et al (2014) Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. Clin Exp Immunol 177:234–43.35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Chimenti MS, Esposito M, Giunta A, Graceffa D, Babino G, Teoli M et al (2013 Jul-Sep) Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients’ clinical characteristics leading to disease relapse. Int J Immunopathol Pharmacol 26(3):833–838

    Article  CAS  PubMed  Google Scholar 

  35. Lorenzin M, Ortolan A, de Hooge M, Frallonardo P, Piccoli A, Cozzi F et al (2015 Sep 17) Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: a single-center retrospective study. Int J Immunopathol Pharmacol

  36. Van den Bosch F, Kavanaugh A, Kron M, Kupper H, Mease PJ (2015) Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. J Rheumatol 42:952–959

    Article  PubMed  Google Scholar 

  37. Ranganath VK, Yoon J, Khanna D, Park GS, Furst DE, Elashoff DA et al (2007) Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis 66:1633–1640

    Article  PubMed  PubMed Central  Google Scholar 

  38. Tillet W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, McHugh N (2013) Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 72:1358–1361

    Article  Google Scholar 

  39. Højgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH et al (2015) Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 74:2130–2136

    Article  PubMed  Google Scholar 

  40. Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, Lindqvist UR (2014) Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish early psoriatic arthritis register (SwePsA). Ann Rheum Dis 73:407–413

    Article  PubMed  Google Scholar 

  41. Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA et al (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147–153

    Article  CAS  PubMed  Google Scholar 

  42. Abou-Raya A, Abou-Raya S (2006) Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 5:331–337

    Article  CAS  PubMed  Google Scholar 

  43. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG et al (2007) Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 75:235–240

    Article  CAS  PubMed  Google Scholar 

  44. Akahane M, Watanabe M, Inoue N, Miyahara Y, Arakawa Y, Inoue Y, Katsumata Y, Hidaka Y, Iwatani Y (2016 May) Association of the polymorphisms of chemokine genes (IL8, RANTES, MIG, IP10, MCP1 and IL16) with the pathogenesis of autoimmune thyroid diseases. Autoimmunity 31:1–8

    Google Scholar 

  45. Triggianese P, Perricone C, Conigliaro P, Chimenti MS, Perricone R, De Carolis C (2016) Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure. Int J Immunopathol Pharmacol 29:65–75

    Article  CAS  PubMed  Google Scholar 

  46. Acay A, Ulu MS, Ahsen A, Eroglu S, Ozuguz U, Yuksel S, Acarturk G (2014) Assessment of thyroid disorders and autoimmunity in patients with rheumatic diseases. Endocr Metab Immune Disord Drug Targets 14:182–186

    Article  CAS  PubMed  Google Scholar 

  47. Marin J, Acosta Felquer ML, Ferreyra Garrot L, Ruta S, Rosa J, Soriano ER (2016 May) Patients with psoriatic arthritis fulfilling the minimal disease activity criteria do not have swollen and tender joints, but have active skin. J Rheumatol 43(5):907–910

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Chimenti Maria Sole and Triggianese Paola equally contributed to this study.

Authors and Affiliations

  1. Rheumatology, Allergology and Clinical Immunology, Department of “Medicina dei Sistemi”, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy

    Maria Sole Chimenti, Paola Triggianese, Paola Conigliaro, Marco Tonelli, Gianfranco Gigliucci, Lucia Novelli, Miriam Teoli & Roberto Perricone

  2. Dermatology, Department of “Medicina dei Sistemi”, University of Rome Tor Vergata, Rome, Italy

    Maria Sole Chimenti, Paola Triggianese, Paola Conigliaro, Marco Tonelli, Gianfranco Gigliucci, Lucia Novelli, Miriam Teoli & Roberto Perricone

Authors
  1. Maria Sole Chimenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola Triggianese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Conigliaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marco Tonelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gianfranco Gigliucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lucia Novelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Miriam Teoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roberto Perricone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Sole Chimenti.

Ethics declarations

The study was carried out according to the Declaration of Helsinki and conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines. The research ethic board of the University of Rome Tor Vergata approved the study (approval number 96.15). All patients provided written informed consent before participating in any study-related activities.

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chimenti, M.S., Triggianese, P., Conigliaro, P. et al. A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors. Clin Rheumatol 36, 2253–2260 (2017). https://doi.org/10.1007/s10067-017-3769-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3769-4

Keywords

Search

Navigation